Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peripheral vascular disorder therapeutics - Alucent Biomedical

Next Previous
Drug Profile

Peripheral vascular disorder therapeutics - Alucent Biomedical

Alternative Names: Alucent NVS Vessel Restoration System - Alucent Biomedical; AlucentNVS - Alucent Biomedical; Natural vascular scaffold therapy; NVS therapy

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alumend
  • Developer Alucent Biomedical
  • Class Small molecules; Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Arteriovenous fistula

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for clinical-Phase-Unknown development in Arteriovenous-fistula(In the elderly, In adults) in Australia
  • 02 Aug 2023 Clinical trials in Arteriovenous fistula in Poland (unspecified route)
  • 15 Jul 2022 Clinical trials in Arteriovenous fistula (In adults, In the elderly) in Australia (unspecified route) (NCT05462223)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top